PharmaMar
Clinical trials sponsored by PharmaMar, explained in plain language.
Biopharmaceutical company developing marine-derived anticancer drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer drug PM54 enters first human tests Results expected Dec 2026 (estimated)
-
New drug combo shows promise for tough cancers
Disease control Recruiting nowThis study tests a new drug called PM54 combined with the immunotherapy pembrolizumab in adults with advanced cancers that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing. About 119 par…
Phase 1/2 • Sponsor: PharmaMar • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New cancer drug PM54 enters first human tests
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called PM54 in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose by watching for side effects, and second, checking if the drug can shrink tu…
Phase 1 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC